Human Investing’s Genomic Health, Inc. GHDX Stock Holding History

Human Investing’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,724	Closed	-$111K	–	445
2018 Q4	$111K	Buy	+1,724	New	+$121K	0.05%	142

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Human Investing's GHDX Position: Q1 2019 in Review

Human Investing sold out of Genomic Health, Inc. (GHDX) in Q1 2019, closing a stake of 1,724 shares — an estimated $111K sold.

Human Investing first reported a position in GHDX in Q4 2018 and held it in 1 quarter. The position peaked at $111K in Q4 2018. 267 funds tracked by Wall St. Rank hold GHDX as of Q1 2019.

Human Investing reported no remaining Genomic Health, Inc. position as of Q1 2019 after selling out during the quarter.
Human Investing sold 1,724 Genomic Health, Inc. shares in Q1 2019, an estimated $111K.
Human Investing first reported a position in Genomic Health, Inc. in Q4 2018 and held it in 1 quarter.
Human Investing's Genomic Health, Inc. position peaked at $111K in Q4 2018.
267 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2019.

Based on Human Investing's 13F filing for Q1 2019, filed 14 May 2019.